Notas del episodio
This episode delves into a novel approach to cancer immunotherapy: in vivo reprogramming of tumor cells into type 1 conventional dendritic cells (cDC1s) using the transcription factors PU.1, IRF8, and BATF3 (PIB).
Key Findings:
- PIB overexpression reprograms tumor cells into cDC1-like cells in vivo, inducing robust, systemic antitumor immunity in mouse melanoma models.
- Reprogrammed tumor cells remodel the tumor microenvironment (TME), recruiting and expanding polyclonal cytotoxic T cells, and forming tertiary lymphoid structure (TLS)-like formations.
- In vivo reprogramming establishes long-term systemic immunity, protecting mice from t ...